

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 723989600 US) in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 2nd day of May2005.

s/ 
Christina M. Compelube

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Benedict, et al.	Group Art Unit: 1625
Serial No.: 10/754,171	Examiner: Aulakh, Charanjit
Confirmation No.: 8481	
Filed: January 9, 2004	Attorney Docket No.: PC25144A
For: TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY	

Mail Stop AMENDMENT
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Sir:

In response to the Office action mailed April 8, 2005, please amend the above-identified application as follows.

☒ **Amendments to the Claims** are reflected in the listing of claims, which begins on page 2 of this paper.

☒ **Remarks** begin on page 24 of this paper.

05/05/2005 EFLORES 00000063 500329 10754171

01 FC:1201 200.00 DA


05-0405

JW

PTO/SB/17 (12-04v2)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Effective on 12/08/2004.

Fees payable to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

For FY 2005

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 200.00

Complete if Known

Application Number	10/754,171
Filing Date	January 9, 2004
First Named Inventor	Suzanne Benedict
Examiner Name	Charanjit Aulakh
Art Unit	1625
Attorney Docket No.	PC25144A

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 500329 Deposit Account Name: Agouron Pharmaceuticals

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description

Each claim over 20 (including Reissues)
Each independent claim over 3 (including Reissues)
Multiple dependent claims

Fee (\$)	Small Entity Fee (\$)
50	25
200	100
360	180

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
37	- 20 or HP = -0-	x \$50	= -0-

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
4	- 3 or HP = 1	x \$200	= \$200

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
	- 100 =	/ 50 =	(round up to a whole number) x	=

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): _____

Fees Paid (\$)


SUBMITTED BY

Signature	<u>Ye Hua</u>	Registration No. (Attorney/Agent) 53,042	Telephone 858.622.3020
Name (Print/Type)	Ye Hua		Date May 2, 2005

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PC25144A
Transmittal Letter for Amendment & Response for
Appln. No. 10/754,171



Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 723989600 US) in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 2nd day of May 2005.

s/ 
Christina M. Compelube

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Benedict, et al.	Group Art Unit: 1625
Serial No.: 10/754,171	Examiner: Aulakh, Charanjit
Confirmation No.: 8481	
Filed: January 9, 2004	Attorney Docket No.: PC25144A
For: TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY	

Mail Stop AMENDMENT
Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450


TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- | | |
|-------------------------|---------------------|
| 1. Amendment & Response | 25 Pages; |
| 2. Fee Transmittal | 1 Page + Duplicate; |
| 3. Return Postcard | 1 Postcard; and |
| 4. Total Fee Due | Deposit Account. |

Respectfully submitted,

Date: May 2, 2005


Ye Hua
Agent For Applicants
Registration No. 53,042

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-3020
Fax: (858) 678-8233